keyword
https://read.qxmd.com/read/38649631/plasma-neurological-biomarkers-as-a-measure-of-neurotoxicity-in-pediatric-dental-general-anesthesia-a-prospective-observational-feasibility-study
#1
JOURNAL ARTICLE
S Chakithandy, H Nazzal, M Matoug-Elwerfelli, S Narasimhan, S Uddin, K S Prabhu, L Zarif, N Mumtaz, A Sharma, M Al-Khelaifi
PURPOSE: Neurotoxicity concerns have been raised over general anesthesia and sedation medication use in children. Such concerns are largely based on animal studies, historical anesthetic agents, and assessment tools, thus warranting further investigations. Blood biomarkers in detecting neuronal inflammation and apoptosis are novel methods for detecting neuronal damage. Therefore, the aim of this feasibility study was to assess the usefulness of the levels of four plasma biomarkers in dental general anesthesia (DGA) as surrogate markers of neurotoxicity in children...
April 22, 2024: European Archives of Paediatric Dentistry: Official Journal of the European Academy of Paediatric Dentistry
https://read.qxmd.com/read/38649346/longitudinal-cognitive-decline-characterizes-the-profile-of-non-pd-manifest-gba1-mutation-carriers
#2
JOURNAL ARTICLE
Benjamin Roeben, Inga Liepelt-Scarfone, Stefanie Lerche, Milan Zimmermann, Isabel Wurster, Ulrike Sünkel, Claudia Schulte, Christian Deuschle, Gerhard W Eschweiler, Walter Maetzler, Thomas Gasser, Daniela Berg, Kathrin Brockmann
With disease-modifying treatment for Parkinson's disease (PD) associated with variants in the glucocerebrosidase gene (GBA1) under way, the challenge to design clinical trials with non-PD-manifest GBA mutation carriers (GBA1NMC ) comes within close reach. To delineate trajectories of motor and non-motor markers as well as serum neurofilament light (sNfL) levels and to evaluate clinical endpoints as outcomes for clinical trials in GBA1NMC , longitudinal data of 56 GBA1NMC carriers and 112 age- and sex-matched GBA1 wildtype participants (GBA1wildtype ) with up to 9 years of follow-up was analyzed using linear mixed-effects models (LMEM) and Kaplan-Meier survival analysis of clinical endpoints for motor and cognitive function...
April 22, 2024: NPJ Parkinson's Disease
https://read.qxmd.com/read/38648605/serum-neurofilament-light-chain-for-multiple-sclerosis-relapses-too-little-too-late
#3
EDITORIAL
Elizabeth Silbermann, Rebecca I Spain
No abstract text is available yet for this article.
May 14, 2024: Neurology
https://read.qxmd.com/read/38648580/temporal-relationship-between-serum-neurofilament-light-chain-and-radiologic-disease-activity-in-patients-with-multiple-sclerosis
#4
JOURNAL ARTICLE
Robert J Fox, Bruce A C Cree, Jérôme de Sèze, Ralf Gold, Hans-Peter Hartung, Douglas Jeffery, Ludwig Kappos, Xavier Montalban, Bianca Weinstock-Guttman, Carol M Singh, Arman Altincatal, Nicholas Belviso, Robin L Avila, Pei-Ran Ho, Ray Su, Robert Engle, Dipen Sangurdekar, Carl de Moor, Elizabeth Fisher, Bernd C Kieseier, Richard A Rudick
BACKGROUND AND OBJECTIVES: Serum neurofilament light chain (sNfL) levels correlate with multiple sclerosis (MS) disease activity, but the dynamics of this correlation are unknown. We evaluated the relationship between sNfL levels and radiologic MS disease activity through monthly assessments during the 24-week natalizumab treatment interruption period in RESTORE (NCT01071083). METHODS: In the RESTORE trial, participants with relapsing forms of MS who had received natalizumab for ≥12 months were randomized to either continue or stop natalizumab and followed with MRI and blood draws every 4 weeks to week 28 and again at week 52 The sNfL was measured, and its dynamics were correlated with the development of gadolinium-enhancing (Gd+) lesions...
May 14, 2024: Neurology
https://read.qxmd.com/read/38648023/perceived-stress-blood-biomarkers-and-cognitive-functioning-in-older-adults
#5
JOURNAL ARTICLE
Pankaja Desai, Ted K S Ng, Kristin R Krueger, Robert S Wilson, Denis A Evans, Kumar B Rajan
INTRODUCTION: There is a substantial gap in knowledge regarding how perceived stress may influence the relationship between serum-measured biomarkers for Alzheimer's disease and cognitive decline. METHODS: This study consists of 1,118 older adult participants from the Chicago Health and Aging Project (CHAP) (60% Black participants and 63% female participants). Linear mixed effects regression models were conducted to examine the role of perceived stress in the association between three blood biomarkers: total tau (t-tau), glial fibrillary acid protein (GFAP), and neurofilament light chain (NfL) on global cognitive decline...
April 16, 2024: Psychosomatic Medicine
https://read.qxmd.com/read/38647181/motor-band-sign-is-specific-for-amyotrophic-lateral-sclerosis-and-corresponds-to-motor-symptoms
#6
JOURNAL ARTICLE
Charlotte Zejlon, Stefan Sennfält, Johannes Finnsson, Bryan Connolly, Sven Petersson, Tobias Granberg, Caroline Ingre
OBJECTIVE: Magnetic resonance imaging can detect neurodegenerative iron accumulation in the motor cortex, called the motor band sign. This study aims to evaluate its sensitivity/specificity and correlations to symptomatology, biomarkers, and clinical outcome in amyotrophic lateral sclerosis. METHODS: This prospective study consecutively enrolled 114 persons with amyotrophic lateral sclerosis and 79 mimics referred to Karolinska University Hospital, and also 31 healthy controls...
April 22, 2024: Annals of Clinical and Translational Neurology
https://read.qxmd.com/read/38645076/associations-between-structural-brain-changes-and-blood-neurofilament-light-chain-protein-in-treatment-resistant-schizophrenia
#7
Brandon-Joe Cilia, Dhamidhu Eratne, Cassandra Wannan, Charles Malpas, Shorena Janelidze, Oskar Hansson, Ian Everall, Chad Bousman, Naveen Thomas, Alexander F Santillo, Dennis Velakoulis, Christos Pantelis
BACKGROUND AND HYPOTHESIS: Around 30% of people with schizophrenia are refractory to antipsychotic treatment (treatment-resistant schizophrenia; TRS). While abnormal structural neuroimaging findings, in particular volume and thickness reductions, are often observed in schizophrenia, it is anticipated that biomarkers of neuronal injury like neurofilament light chain protein (NfL) can improve our understanding of the pathological basis underlying schizophrenia. The current study aimed to determine whether people with TRS demonstrate different associations between plasma NfL levels and regional cortical thickness reductions compared with controls...
April 8, 2024: medRxiv
https://read.qxmd.com/read/38644997/cytoarchitectonic-gradients-of-laminar-degeneration-in-behavioral-variant-frontotemporal-dementia
#8
Daniel T Ohm, Sharon X Xie, Noah Capp, Sanaz Arezoumandan, Katheryn A Q Cousins, Katya Rascovsky, David A Wolk, Vivianna M Van Deerlin, Edward B Lee, Corey T McMillan, David J Irwin
Behavioral variant frontotemporal dementia (bvFTD) is a clinical syndrome primarily caused by either tau (bvFTD-tau) or TDP-43 (bvFTD-TDP) proteinopathies. We previously found lower cortical layers and dorsolateral regions accumulate greater tau than TDP-43 pathology; however, patterns of laminar neurodegeneration across diverse cytoarchitecture in bvFTD is understudied. We hypothesized that bvFTD-tau and bvFTD-TDP have distinct laminar distributions of pyramidal neurodegeneration along cortical gradients, a topologic order of cytoarchitectonic subregions based on increasing pyramidal density and laminar differentiation...
April 9, 2024: bioRxiv
https://read.qxmd.com/read/38644682/pathologic-and-cognitive-correlates-of-plasma-biomarkers-in-neurodegenerative-disease
#9
JOURNAL ARTICLE
Katheryn A Q Cousins, Jeffrey S Phillips, Sandhitsu R Das, Kyra O'Brien, Thomas F Tropea, Alice Chen-Plotkin, Leslie M Shaw, Ilya M Nasrallah, Dawn Mechanic-Hamilton, Corey T McMillan, David J Irwin, Edward B Lee, David A Wolk
INTRODUCTION: We investigate pathological correlates of plasma phosphorylated tau 181 (p-tau181 ), glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL) across a clinically diverse spectrum of neurodegenerative disease, including normal cognition (NormCog) and impaired cognition (ImpCog). METHODS: Participants were NormCog (n = 132) and ImpCog (n = 461), with confirmed β-amyloid (Aβ+/-) status (cerebrospinal fluid, positron emission tomography, autopsy) and single molecule array plasma measurements...
April 21, 2024: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
https://read.qxmd.com/read/38643887/correlations-among-serum-alpha-1-6-fucosyltransferase-and-early-symptoms-associated-with-parkinson-s-disease-a-cross-sectional-retrospective-study
#10
JOURNAL ARTICLE
Qi-Rong Wang, Xue Yu, Yang Li, Ming-Zhen Zhu
Alpha-(1,6)-fucosyltransferase (FUT8) has been found to play a role in modulating the central immune system and inflammatory responses. Limited studies have assessed the correlations between serum FUT8 levels and various non-motor symptoms associated with early Parkinson's disease (PD). Therefore, our research aims to investigate the associations between serum FUT8 levels and symptoms such as smell dysfunction, sleep duration, sleep problems, and MMSE scores in PD patients. FUT8 and neurofilament light chain (NfL) levels were measured using enzyme-linked immunosorbent assays (ELISA)...
April 19, 2024: Brain Research Bulletin
https://read.qxmd.com/read/38643230/serum-neurofilament-light-chain-and-inflammatory-cytokines-as-biomarkers-for-early-detection-of-mild-cognitive-impairment
#11
JOURNAL ARTICLE
Xinyang Jing, Lan Wang, Mei Song, Hao Geng, Wei Li, Yaxin Huo, Anqi Huang, Xueyi Wang, Cuixia An
To investigate the association between serum neurofilament light chain (NfL) levels, inflammatory cytokines, and cognitive function to assess their utility in the early detection of mild cognitive impairment (MCI). We conducted a cross-sectional study involving 157 community-dwelling individuals aged 55 years and above, categorized into healthy controls, MCI, and probable Alzheimer's disease (AD). Serum levels of NfL, inflammatory cytokines, and AD pathology markers were measured using enzyme-linked immunosorbent assay (ELISA)...
April 20, 2024: Scientific Reports
https://read.qxmd.com/read/38641750/an-autoantibody-signature-predictive-for-multiple-sclerosis
#12
JOURNAL ARTICLE
Colin R Zamecnik, Gavin M Sowa, Ahmed Abdelhak, Ravi Dandekar, Rebecca D Bair, Kristen J Wade, Christopher M Bartley, Kerry Kizer, Danillo G Augusto, Asritha Tubati, Refujia Gomez, Camille Fouassier, Chloe Gerungan, Colette M Caspar, Jessica Alexander, Anne E Wapniarski, Rita P Loudermilk, Erica L Eggers, Kelsey C Zorn, Kirtana Ananth, Nora Jabassini, Sabrina A Mann, Nicholas R Ragan, Adam Santaniello, Roland G Henry, Sergio E Baranzini, Scott S Zamvil, Joseph J Sabatino, Riley M Bove, Chu-Yueh Guo, Jeffrey M Gelfand, Richard Cuneo, H-Christian von Büdingen, Jorge R Oksenberg, Bruce A C Cree, Jill A Hollenbach, Ari J Green, Stephen L Hauser, Mitchell T Wallin, Joseph L DeRisi, Michael R Wilson
Although B cells are implicated in multiple sclerosis (MS) pathophysiology, a predictive or diagnostic autoantibody remains elusive. In this study, the Department of Defense Serum Repository (DoDSR), a cohort of over 10 million individuals, was used to generate whole-proteome autoantibody profiles of hundreds of patients with MS (PwMS) years before and subsequently after MS onset. This analysis defines a unique cluster in approximately 10% of PwMS who share an autoantibody signature against a common motif that has similarity with many human pathogens...
April 19, 2024: Nature Medicine
https://read.qxmd.com/read/38641028/therapeutic-efficacy-of-cinnamein-a-component-of-balsam-of-tolu-peru-in-controlled-cortical-impact-mouse-model-of-tbi
#13
JOURNAL ARTICLE
Jit Poddar, Suresh B Rangasamy, Kalipada Pahan
Traumatic brain injury (TBI) remains a major health concern which causes long-term neurological disability particularly in war veterans, athletes and young adults. In spite of intense clinical and research investigations, there is no effective therapy to cease the pathogenesis of the disease. It is believed that axonal injury during TBI is potentiated by neuroinflammation and demyelination and/or failure to remyelination. This study highlights the use of naturally available cinnamein, also chemically known as benzyl cinnamate, in inhibiting neuroinflammation, promoting remyelination and combating the disease process of controlled cortical impact (CCI)-induced TBI in mice...
April 17, 2024: Neurochemistry International
https://read.qxmd.com/read/38636323/serum-neurofilament-light-chain-inflammatory-markers-and-kynurenine-metabolites-in-patients-with-persistent-post-concussion-symptoms-a-cohort-study
#14
JOURNAL ARTICLE
Peter Preben Eggertsen, Johan Palmfeldt, Asger Roer Pedersen, Oana-Veronica Frederiksen, Rikke Katrine Jentoft Olsen, Jørgen Feldbæk Nielsen
BACKGROUND: Concussion leads to persistent post-concussion symptoms (PPCS) in up to one-third of those affected. While previous research has linked the initial trauma to elevated serum levels of neurofilament light chain (NFL), inflammatory markers, and neurotoxic metabolites within the kynurenine pathway, few studies have explored their relevance in PPCS. This study aims to investigate these biomarkers in PPCS patients, elucidating their relevance in the prolonged phase of concussion...
April 15, 2024: Journal of the Neurological Sciences
https://read.qxmd.com/read/38631769/biomarkers-for-progressive-multifocal-leukoencephalopathy-emerging-data-for-use-of-jc-virus-dna-copy-number-in-clinical-trials
#15
REVIEW
Irene Cortese, Gina Norato, Patrick R Harrington, Therri Usher, Ilaria Mainardi, Guillaume Martin-Blondel, Paola Cinque, Eugene O Major, Virginia Sheikh
Progressive multifocal leukoencephalopathy is a rare but devastating demyelinating disease caused by the JC virus (JCV), for which no therapeutics are approved. To make progress towards addressing this unmet medical need, innovations in clinical trial design are needed. Quantitative JCV DNA in CSF has the potential to serve as a valuable biomarker of progressive multifocal leukoencephalopathy disease and treatment response in clinical trials to expedite therapeutic development, as do neuroimaging and other fluid biomarkers such as neurofilament light chain...
May 2024: Lancet Neurology
https://read.qxmd.com/read/38627753/pathophysiology-characterization-of-alzheimer-s-disease-in-south-china-s-aging-population-for-the-greater-bay-area-healthy-aging-brain-study-ghabs
#16
JOURNAL ARTICLE
Zhen Liu, Dai Shi, Yue Cai, Anqi Li, Guoyu Lan, Pan Sun, Lin Liu, Yalin Zhu, Jie Yang, Yajing Zhou, Lizhi Guo, Laihong Zhang, Shuqing Deng, Shuda Chen, Xianfeng Yu, Xuhui Chen, Ruiyue Zhao, Qingyong Wang, Pengcheng Ran, Linsen Xu, Liemin Zhou, Kun Sun, Xinlu Wang, Qiyu Peng, Ying Han, Tengfei Guo
INTRODUCTION: The Guangdong-Hong Kong-Macao Greater-Bay-Area of South China has an 86 million population and faces a significant challenge of Alzheimer's disease (AD). However, the characteristics and prevalence of AD in this area are still unclear due to the rarely available community-based neuroimaging AD cohort. METHODS: Following the standard protocols of the Alzheimer's Disease Neuroimaging Initiative, the Greater-Bay-Area Healthy Aging Brain Study (GHABS) was initiated in 2021...
April 16, 2024: Alzheimer's Research & Therapy
https://read.qxmd.com/read/38627748/cluster-analysis-dissecting-cognitive-deficits-in-older-adults-with-major-depressive-disorder-and-the-association-with-neurofilament-light-chain
#17
JOURNAL ARTICLE
Cynthia Yi-An Chen, Chih-Chiang Chiu, Cho-Yin Huang, Ying-Chih Cheng, Ming-Chyi Huang, Po-Hsiu Kuo, Wen-Yin Chen
BACKGROUND: Cognitive impairment is a growing problem with increasing burden in global aging. Older adults with major depressive disorder (MDD) have higher risk of dementia. Neurofilament light chain (NfL) has been proven as a potential biomarker in neurodegenerative disease, including dementia. We aimed to investigate the association between cognitive deficits and NfL levels in older adults with MDD. METHODS: In this cross-sectional study, we enrolled 39 MDD patients and 15 individuals with mild neurocognitive disorder or major neurocognitive disorder, Alzheimer's type, as controls, from a tertiary psychiatric hospital...
April 16, 2024: BMC Geriatrics
https://read.qxmd.com/read/38626384/associations-between-blood-based-biomarkers-and-cognitive-and-functional-trajectories-among-participants-of-the-memento-cohort
#18
JOURNAL ARTICLE
Leslie Grasset, Vincent Bouteloup, Federica Cacciamani, Isabelle Pellegrin, Vincent Planche, Geneviève Chêne, Carole Dufouil
BACKGROUND AND OBJECTIVES: Elevated levels of Alzheimer disease (AD) blood-based biomarkers are associated with accelerated cognitive decline. However, their distinct relationships with specific cognitive and functional domains require further investigation. We aimed at estimating the associations between AD blood-based biomarkers and the trajectories of distinct cognitive and functional domains over a 5-year follow-up period. METHODS: We conducted a clinic-based prospective study using data from the MEMENTO study, a nationwide French cohort...
May 2024: Neurology
https://read.qxmd.com/read/38623387/relationship-of-plasma-biomarkers-to-digital-cognitive-tests-in-alzheimer-s-disease
#19
JOURNAL ARTICLE
Sofia Toniolo, Sijia Zhao, Anna Scholcz, Benazir Amein, Akke Ganse-Dumrath, Amanda J Heslegrave, Sian Thompson, Sanjay Manohar, Henrik Zetterberg, Masud Husain
INTRODUCTION: A major limitation in Alzheimer's disease (AD) research is the lack of the ability to measure cognitive performance at scale-robustly, remotely, and frequently. Currently, there are no established online digital platforms validated against plasma biomarkers of AD. METHODS: We used a novel web-based platform that assessed different cognitive functions in AD patients ( N  = 46) and elderly controls ( N  = 53) who were also evaluated for plasma biomarkers (amyloid beta 42/40 ratio, phosphorylated tau ([p-tau]181, glial fibrillary acidic protein, neurofilament light chain)...
2024: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
https://read.qxmd.com/read/38623384/cognitive-and-functional-performance-and-plasma-biomarkers-of-early-alzheimer-s-disease-in-down-syndrome
#20
JOURNAL ARTICLE
Emily K Schworer, Benjamin L Handen, Melissa Petersen, Sid O'Bryant, Jamie C Peven, Dana L Tudorascu, Laisze Lee, Sharon J Krinsky-McHale, Christy L Hom, Isabel C H Clare, Bradley T Christian, Nicole Schupf, Joseph H Lee, Elizabeth Head, Mark Mapstone, Ira Lott, Beau M Ances, Shahid Zaman, Adam M Brickman, Florence Lai, H Diana Rosas, Sigan L Hartley
INTRODUCTION: People with Down syndrome (DS) have a 75% to 90% lifetime risk of Alzheimer's disease (AD). AD pathology begins a decade or more prior to onset of clinical AD dementia in people with DS. It is not clear if plasma biomarkers of AD pathology are correlated with early cognitive and functional impairments in DS, and if these biomarkers could be used to track the early stages of AD in DS or to inform inclusion criteria for clinical AD treatment trials. METHODS: This large cross-sectional cohort study investigated the associations between plasma biomarkers of amyloid beta (Aβ)42/40, total tau, and neurofilament light chain (NfL) and cognitive (episodic memory, visual-motor integration, and visuospatial abilities) and functional (adaptive behavior) impairments in 260 adults with DS without dementia (aged 25-81 years)...
2024: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
keyword
keyword
62073
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.